Bristol Myers Squibb Stock - analyst consensus and technical picture on Thursday
18.06.2026 - 13:44:23 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 11:40 UTC. Details in the imprint.
Bristol Myers Squibb (US0897961004) remains a core U.S. large-cap pharma name on the New York Stock Exchange. With no fresh company news from its investor relations page or major wires this Thursday, the focus shifts to analyst expectations and the stock's medium-term chart picture.
All news and key data on Bristol Myers Squibb stock
Background reports, corporate news and historical price data for Bristol Myers Squibb stock can be found bundled on the dedicated topic page and via the company's investor relations site.
What analysts currently expect
Without a fresh catalyst today, attention turns to the sell-side stance on Bristol Myers Squibb. According to recent consensus data compiled on major financial portals, analysts are split roughly between Buy and Hold recommendations for the stock.
Average 12-month price targets cluster modestly above the current trading range, implying single-digit percentage upside from today's levels. Price objectives vary, though, reflecting differing views on the company's loss of exclusivity risks and its newer product launches.
How earnings estimates look
For the current fiscal year, consensus forecasts see Bristol Myers Squibb generating mid-single-digit billion-dollar quarterly revenues, driven by oncology and cardiovascular therapies. Earnings per share are projected to remain under pressure as the group invests in its pipeline and digests prior acquisitions.
Forecast dispersion has widened compared with last year, a sign that analysts see greater uncertainty around key drugs and the timing of potential new approvals. Against this backdrop, estimate revisions in recent months have been mixed rather than clearly positive or negative.
The technical picture around key levels
On the chart, Bristol Myers Squibb shares trade below their 200-day moving average, a level many technical traders watch as a long-term trend gauge. The long-term average has been edging lower, reflecting the stock's weaker phase over the past year.
Shorter-term moving averages remain clustered not far from the current price range, signaling a consolidation rather than a clear directional trend. Volatility has been muted compared with the sharp moves seen during prior major pipeline and patent headlines.
How the stock compares with peers
Versus other big pharma names in the Standard & Poor's 500 index, Bristol Myers Squibb stock trades on a discount valuation on several common metrics. Its price-to-earnings and price-to-sales ratios sit below the sector average, reflecting investor caution.
Dividend yield, however, is higher than many direct peers, which may appeal to income-focused investors. The balance between valuation support and pipeline uncertainty continues to shape how the shares are positioned within healthcare portfolios.
How the company makes money
Bristol Myers Squibb generates most of its revenue from prescription medicines in oncology, hematology, immunology and cardiovascular disease. Flagship products include the cancer drug Opdivo and the anticoagulant Eliquis, alongside a broader portfolio of specialty therapies.
Where the stock trades today
The shares of Bristol Myers Squibb (US0897961004) trade on the New York Stock Exchange at around $40.00 as of 06/18/2026, 11:30 ET.
Key facts on Bristol Myers Squibb stock
- Company: Bristol-Myers Squibb Company
- ISIN: US0897961004
- WKN: 850501
- Ticker: BMY
- Venue: New York Stock Exchange
- Price (as of 06/18/2026, 11:30 ET): 40.00 USD
- Market cap: 81,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
